US FDA accepts Bristol Myers Squibb's (BMY) new drug application for Iberdomide in patients with relapsed or refractory multiple Myeloma; target action date of August 17th

US FDA accepts Bristol Myers Squibb's (BMY) new drug application for Iberdomide in patients with relapsed or refractory multiple Myeloma; target action date of August 17th.

Bristol Myers Squibb's new drug application for Iberdomide has been accepted by the FDA, marking a significant potential milestone for the company in the oncology space. The upcoming target action date of August 17th will be critical, as approval could drive future revenue growth and positively impact stock performance, especially if market expectations shift favorably as a result.